[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.179.146. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
April 1989

Cyclosporine in Lamellar Ichthyosis

Author Affiliations

From the Departments of Dermatology (Drs Ho, Gupta, Ellis, Cooper, Nickoloff, and Voorhees) and Pathology (Dr Nickoloff), University of Michigan Medical Center, Ann Arbor, and the Dermatology Service, Ann Arbor Veterans Administration Hospital (Dr Cooper). Dr Ho is now a fellow with the Department of Dermatology, Harvard University School of Medicine, Boston.

Arch Dermatol. 1989;125(4):511-514. doi:10.1001/archderm.1989.01670160059008
Abstract

• In an open trial, five patients with lamellar ichthyosis showed no response to four weeks of treatment with oral cyclosporine (cyclosporine A) (6 mg/kg/d). Histologic examination of lamellar ichthyosis revealed hyperkeratosis; psoriasiform acanthosis; dilated, tortuous capillaries; and a slight perivascular lymphocytic infiltrate. Immunofluorescence studies revealed, in the epidermis, normal numbers of T6+DR+ Langerhans' cells and an absence of T cells and intercellular adhesion molecule-1 expression. In the papillary dermis, there were prominent capillaries as detected by staining with anti-factor VIII-related antigen. The endothelial cells also expressed large amounts of HLA-DR and intercellular adhesion molecule-1, suggesting that they were activated. Only occasional Langerhans' cells were found in the dermis. Histologic and immunofluorescence findings were unchanged with cyclosporine therapy. The effects of cyclosporine on lamellar ichthyosis are contrasted with those reported for psoriasis. Since lamellar ichthyosis and psoriasis share similar features of epidermal hyperproliferation and the presence of activated, dilated, tortuous vessels, but differ in the lack of immunologic cellular activity, their contrasting response to cyclosporine suggests that the target of the action of cyclosporine is the immune system rather than the keratinocyte or the endothelium. However, other factors may have to be considered.

(Arch Dermatol 1989;125:511-514)

×